JonesResearch initiated coverage of OnKure Therapeutics (OKUR) with a Buy rating and $32 price target. The clinical stage precision oncology ...
Relay Therapeutics (market cap: $748.2 million), a biotechnology company focused on developing innovative cancer therapies, ...
Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...
JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target of ...
Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.
In the tough market conditions last year, investors and big pharma companies were more likely to place their bets on later, clinical-stage companies. But local biotech leaders see signs of change in ...
GlobalData on MSN15d
Eli Lilly targets Scorpion Therapeutics to expand reach in oncologyEli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away to form a new entity with its remaining assets. Lilly’s bid to acquire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback